Suppliers and packagers for harvoni

harvoni

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477	NDA	Gilead Sciences, Inc	61958-1804-1	120 PELLET in 1 PACKET (61958-1804-1)	2019-08-28
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477	NDA	Gilead Sciences, Inc	61958-1805-1	90 PELLET in 1 PACKET (61958-1805-1)	2019-08-28
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834	NDA	Gilead Sciences, Inc	61958-1801-1	28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1801-1)	2014-10-10
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834	NDA	Gilead Sciences, Inc	61958-1803-1	28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1803-1)	2019-08-28
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834	NDA AUTHORIZED GENERIC	Asegua Therapeutics LLC	72626-2601-1	2 BLISTER PACK in 1 CARTON (72626-2601-1) / 14 TABLET, FILM COATED in 1 BLISTER PACK	2019-01-01

Suppliers for Harvoni (Ledipasvir/Sofosbuvir)

Last updated: February 19, 2026

Harvoni, a fixed-dose combination of ledipasvir and sofosbuvir, is a direct-acting antiviral (DAA) medication developed by Gilead Sciences for the treatment of chronic hepatitis C virus (HCV) infection. The successful and cost-effective production of Harvoni relies on a complex supply chain involving multiple active pharmaceutical ingredient (API) suppliers and contract manufacturing organizations (CMOs).

Key Suppliers and Manufacturers

Gilead Sciences holds the primary patent and manufacturing rights for Harvoni. However, the production of its constituent APIs, ledipasvir and sofosbuvir, involves a network of specialized chemical manufacturers. The final drug product is typically manufactured by Gilead or its designated CMOs.

API Suppliers

The synthesis of complex molecules like ledipasvir and sofosbuvir requires advanced chemical manufacturing capabilities. Key suppliers for these APIs often include companies with expertise in custom synthesis and large-scale pharmaceutical ingredient production. While specific contractual relationships are often confidential, the landscape of API manufacturing for such high-value drugs includes established players in India and China, known for their cost-effectiveness and technical prowess.

• Ledipasvir API Suppliers:
  • Companies specializing in complex organic synthesis are critical for ledipasvir production. These firms often operate under strict Good Manufacturing Practice (GMP) regulations.
  • Examples of regions with a significant presence of such suppliers include India, which has a well-established pharmaceutical chemical industry.
• Sofosbuvir API Suppliers:
  • Sofosbuvir's synthesis is also intricate, involving nucleoside chemistry.
  • Manufacturers with experience in nucleotide and nucleoside analogs are key. Similar to ledipasvir, India and China are prominent sources for sofosbuvir API.

Contract Manufacturing Organizations (CMOs)

The formulation of APIs into the final dosage form (tablets) and packaging is frequently outsourced to CMOs. These organizations provide specialized manufacturing services, allowing pharmaceutical companies to scale production efficiently.

• Finished Dosage Form (FDF) Manufacturing:
  • Gilead Sciences may utilize internal manufacturing facilities or engage external CMOs for the production of Harvoni tablets.
  • CMOs capable of high-volume tablet manufacturing, quality control, and adherence to stringent regulatory standards (FDA, EMA) are essential.
  • Companies with experience in solid oral dosage forms and handling potent compounds are preferred.

Supply Chain Dynamics and Patent Landscape

The supply chain for Harvoni is influenced by Gilead's intellectual property rights, including patents covering the composition of matter for ledipasvir and sofosbuvir, as well as methods of use and manufacturing processes.

Patent Protection

Gilead Sciences holds extensive patent protection for Harvoni. Key patents include those covering:

• Composition of Matter: Patents for ledipasvir and sofosbuvir themselves, typically with expiration dates in the mid-2030s. For example, U.S. Patent No. 8,759,285 (issued June 24, 2014) is associated with sofosbuvir. Ledipasvir is protected by patents such as U.S. Patent No. 8,907,063 (issued December 9, 2014).
• Combination Therapies: Patents covering the fixed-dose combination of ledipasvir and sofosbuvir.
• Manufacturing Processes: Patents detailing specific chemical synthesis routes and purification methods.

These patents grant Gilead exclusive rights to manufacture and sell Harvoni, influencing the market structure and limiting the ability of generic manufacturers to enter until patent expiry or through licensing agreements.

Generic Competition and Licensing

As patents approach expiration, or in regions with different patent laws, generic manufacturers seek to produce and market their own versions of Harvoni. This often involves:

• Paragraph IV Certifications: In the United States, generic companies may challenge existing patents by filing an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification, asserting that the patent is invalid, unenforceable, or will not be infringed. This can lead to patent litigation.
• Licensing Agreements: Gilead has entered into voluntary licensing agreements with certain generic manufacturers, particularly in low- and middle-income countries. These agreements permit licensed companies to produce and sell generic versions of Harvoni at reduced prices, improving access to treatment. For instance, Gilead has partnered with companies like Cipla, Mylan, and others through the Medicines Patent Pool to facilitate access in developing nations.

Manufacturing and Quality Control

The production of pharmaceuticals like Harvoni necessitates rigorous adherence to quality standards to ensure patient safety and drug efficacy.

Good Manufacturing Practices (GMP)

All manufacturing facilities involved in the production of Harvoni, from API synthesis to final drug product formulation, must comply with GMP regulations set forth by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). GMP ensures:

• Process Consistency: Standardized procedures and controls to ensure consistent product quality.
• Purity and Potency: Verification of the chemical purity and correct potency of APIs and the finished drug product.
• Contamination Prevention: Measures to prevent cross-contamination and microbial contamination.
• Traceability: Comprehensive documentation and record-keeping for batch traceability.

Analytical Testing and Quality Assurance

Extensive analytical testing is conducted at various stages of the manufacturing process:

• Raw Material Testing: Verification of the identity, purity, and quality of all incoming raw materials and reagents used in API synthesis.
• In-Process Controls: Monitoring of critical parameters during chemical synthesis to ensure reactions proceed as intended and to detect potential deviations early.
• API Release Testing: Comprehensive analysis of the final API batches for purity, assay, impurity profiles, and physical characteristics.
• Finished Product Testing: Analysis of the final Harvoni tablets for dissolution, uniformity of dosage units, content of active ingredients, and presence of degradation products.

Global Supply Chain Considerations

The global nature of pharmaceutical manufacturing means that suppliers for Harvoni can be located in various countries, each with its own regulatory framework and economic considerations.

Geographic Diversification

To mitigate risks and optimize costs, pharmaceutical companies often diversify their supplier base across different geographical regions. This can include sourcing raw materials, intermediates, and APIs from countries like:

• India: A major hub for API manufacturing and generic drug production, known for its cost-effectiveness and established chemical industry.
• China: Another significant global supplier of APIs and chemical intermediates, offering large-scale manufacturing capabilities.
• Europe and North America: Some specialized APIs or advanced intermediates may be sourced from manufacturers in these regions, particularly for high-value or complex syntheses requiring specific technological expertise or stringent regulatory compliance.

Regulatory Compliance and Audits

Suppliers for a product like Harvoni are subject to rigorous regulatory oversight. This involves:

• Facility Audits: Regular audits by Gilead Sciences and regulatory agencies (FDA, EMA) to ensure compliance with GMP and other quality standards.
• Drug Master Files (DMFs): API suppliers typically submit DMFs to regulatory agencies, providing detailed information about their manufacturing processes, facilities, and quality control. This information is reviewed by regulatory bodies when assessing drug applications.
• Supply Chain Security: Measures to ensure the security and integrity of the supply chain, preventing counterfeiting and ensuring product authenticity.

Economic and Market Factors

The supply chain for Harvoni is also shaped by economic considerations, including the cost of raw materials, manufacturing efficiency, and global demand.

Cost of Goods Sold (COGS)

The COGS for Harvoni is influenced by:

• API Manufacturing Costs: The complexity of ledipasvir and sofosbuvir synthesis significantly impacts their production cost. Efficiency gains through process optimization and economies of scale are crucial.
• Formulation and Packaging: The cost of transforming APIs into finished tablets and packaging them.
• Raw Material Prices: Fluctuations in the prices of basic chemicals and reagents used in API synthesis.

Market Access and Pricing

The high cost of Harvoni at launch was a significant factor in market access discussions. The development of generic versions, facilitated by licensing agreements and patent expirations, has led to reduced prices and improved affordability in many regions. This, in turn, impacts the demand for APIs and the revenue streams for suppliers.

Key Takeaways

• Harvoni's production involves specialized API suppliers and CMOs globally, with a significant presence in India and China for API manufacturing.
• Gilead Sciences holds primary patent rights for Harvoni, influencing market entry for generic alternatives.
• Voluntary licensing agreements have enabled broader access to generic Harvoni in lower-income countries.
• Manufacturing requires strict adherence to GMP, with extensive quality control and analytical testing at all stages.
• Supply chain resilience and regulatory compliance are paramount, involving frequent audits and detailed documentation.
• Economic factors, including API production costs and raw material prices, directly impact Harvoni's overall manufacturing cost.

Frequently Asked Questions

1. Who are the primary API manufacturers for ledipasvir and sofosbuvir? While specific supplier contracts are proprietary, API manufacturing for ledipasvir and sofosbuvir is typically undertaken by specialized chemical synthesis companies with advanced GMP capabilities, often located in India and China.

2. Does Gilead Sciences manufacture Harvoni internally, or does it rely entirely on CMOs? Gilead Sciences utilizes a combination of internal manufacturing capabilities and contract manufacturing organizations for the production of Harvoni.

3. What is the typical expiration date for key patents covering Harvoni? Key patents for the composition of matter for ledipasvir and sofosbuvir, as well as their combination, generally extend into the mid-2030s, though specific expiration dates can vary by jurisdiction and patent.

4. How do voluntary licensing agreements affect the supply chain for Harvoni? These agreements allow selected generic manufacturers to produce and distribute Harvoni in specific regions, increasing the number of API and finished product suppliers in those markets and often leading to price reductions.

5. What are the primary quality control measures for Harvoni production? Production adheres to strict GMP guidelines, involving raw material testing, in-process controls, API release testing for purity and potency, and finished product analysis for dissolution, content uniformity, and degradation products.

Citations

[1] U.S. Patent No. 8,759,285. (2014). Prodrugs of 2′-deoxy-2′-fluoro-2′-methyluridine. Issued June 24, 2014. [2] U.S. Patent No. 8,907,063. (2014). Imidazopyridine derivatives. Issued December 9, 2014.